Literature DB >> 8537675

Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with Schistosoma mansoni.

E A Sabin1, M I Araujo, E M Carvalho, E J Pearce.   

Abstract

After vaccination with tetanus toxoid (TT), TT-specific immune responses in humans infected with Schistosoma mansoni were assessed. Peripheral blood mononuclear cells (PBMC) from vaccinated infected subjects and vaccinated uninfected controls were evaluated for their ability to produce cytokines characteristic of Th1 or Th2 cells (interferon [IFN]-gamma or interleukin [IL]-4, respectively) after in vitro restimulation with TT. TT-specific IFN-gamma production by PBMC from infected subjects was inversely related to infection intensity and was significantly lower than TT-specific IFN-gamma production by control PBMC. PBMC from all of the infected subjects and 3 of the 5 controls analyzed by reverse transcriptase-polymerase chain reaction transcribed the IL-4 gene in response to TT restimulation. Together, these results suggest that S. mansoni-infected persons mount a Th2-like response to the bystander antigen TT, while uninfected persons mount a Th1- or Th0-like response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8537675     DOI: 10.1093/infdis/173.1.269

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  121 in total

Review 1.  Immunology of parasitic helminth infections.

Authors:  Andrew S MacDonald; Maria Ilma Araujo; Edward J Pearce
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

Review 2.  Host background immunity and human immunodeficiency virus protective vaccines, a major consideration for vaccine efficacy in Africa and in developing countries.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

3.  Interleukin-12 is capable of generating an antigen-specific Th1-type response in the presence of an ongoing infection-driven Th2-type response.

Authors:  L R Schopf; J L Bliss; L M Lavigne; C L Chung; S F Wolf; J P Sypek
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

4.  Helminths and harmony.

Authors:  J V Weinstock; R Summers; D E Elliott
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

5.  Concurrent infection with an intestinal helminth parasite impairs host resistance to enteric Citrobacter rodentium and enhances Citrobacter-induced colitis in mice.

Authors:  Chien-Chang Chen; Steve Louie; Beth McCormick; W Allan Walker; Hai Ning Shi
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

6.  Previous or ongoing schistosome infections do not compromise the efficacy of the attenuated cercaria vaccine.

Authors:  Thomas M Kariuki; Govert J Van Dam; André M Deelder; Idle O Farah; Dorcas S Yole; R Alan Wilson; Patricia S Coulson
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 7.  Helminth infections and host immune regulation.

Authors:  Henry J McSorley; Rick M Maizels
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 8.  Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Schistosomiasis Induces Persistent DNA Methylation and Tuberculosis-Specific Immune Changes.

Authors:  Andrew R DiNardo; Tomoki Nishiguchi; Emily M Mace; Kimal Rajapakshe; Godwin Mtetwa; Alexander Kay; Gugu Maphalala; W Evan Secor; Rojelio Mejia; Jordan S Orange; Cristian Coarfa; Kapil N Bhalla; Edward A Graviss; Anna M Mandalakas; George Makedonas
Journal:  J Immunol       Date:  2018-05-11       Impact factor: 5.422

Review 10.  Immunomodulation in Plasmodium falciparum malaria: experiments in nature and their conflicting implications for potential therapeutic agents.

Authors:  Anne E P Frosch; Chandy C John
Journal:  Expert Rev Anti Infect Ther       Date:  2012-11       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.